Linear regression analysis for DKK3 concentrations in the verification cohort
| Factor . | n . | Simple regression . | Multiple regression . | ||
|---|---|---|---|---|---|
| Fold difference* (95% CI) . | P . | Fold difference* (95% CI) . | P . | ||
| Main comparison | <.001† | <.001† | |||
| No GVHD | 62 | Reference | Reference | ||
| Chronic GVHD without steroid | 37 | 1.40 (1.21-1.63) | <.001 | 1.40 (1.21-1.61) | <.001 |
| Chronic GVHD with steroid | 87 | 1.84 (1.63-2.07) | <.001 | 1.83 (1.63-2.05) | <.001 |
| Patient age at sample, continuous (per decade) | 186 | 1.08 (1.03-1.13) | .003 | 1.07 (1.03-1.12) | .001 |
| Patient sex | |||||
| Male | 96 | Reference | |||
| Female | 90 | 0.99 (0.87-1.13) | .92 | ||
| Race | |||||
| White | 167 | Reference | |||
| Others | 19 | 0.92 (0.74-1.14) | .45 | ||
| Stem cell source | .06† | ||||
| Peripheral blood stem cell | 162 | Reference | |||
| Bone marrow | 18 | 0.82 (0.66-1.03) | .083 | ||
| Cord blood | 5 | 0.65 (0.44-0.97) | .035 | ||
| Missing | 1 | 0.74 (0.31-1.80) | .51 | ||
| Conditioning intensity | |||||
| Myeloablative | 96 | Reference | |||
| Reduced intensity | 90 | 1.17 (1.03-1.33) | .02 | ||
| Donor type | .29† | ||||
| HLA-matched relative | 68 | Reference | |||
| HLA-mismatched relative | 7 | 0.94 (0.66-1.34) | .75 | ||
| Unrelated donor | 111 | 1.10 (0.96-1.27) | .16 | ||
| Female donor to a male recipient | 37 | 1.05 (0.89-1.24) | .57 | ||
| Prior grade 2-4 acute GVHD | 108 | 0.99 (0.86-1.13) | .84 | ||
| Duration from HCT to sample draw per y | 186 | 1.08 (1.02-1.15) | .007 | ||
| NIH global severity | <.001† | ||||
| None or mild | 101 | Reference | |||
| Moderate | 35 | 1.41 (1.20-1.66) | <.001 | ||
| Severe | 50 | 1.51 (1.31-1.75) | <.001 | ||
| Involved sites | |||||
| Skin | 74 | 1.40 (1.24-1.58) | <.001 | ||
| Mouth | 58 | 1.34 (1.17-1.54) | <.001 | ||
| Eye | 72 | 1.51 (1.34-1.71) | <.001 | ||
| Gastrointestinal tract | 24 | 1.32 (1.09-1.60) | .005 | ||
| Liver | 5 | 1.24 (0.83-1.86) | .29 | ||
| Lung (bronchiolitis obliterans) | 4 | 1.38 (0.88-2.16) | .16 | ||
| Joint/fascia | 57 | 1.38 (1.21-1.58) | <.001 | ||
| Genital | 15 | 1.15 (0.91-1.47) | .24 | ||
| Factor . | n . | Simple regression . | Multiple regression . | ||
|---|---|---|---|---|---|
| Fold difference* (95% CI) . | P . | Fold difference* (95% CI) . | P . | ||
| Main comparison | <.001† | <.001† | |||
| No GVHD | 62 | Reference | Reference | ||
| Chronic GVHD without steroid | 37 | 1.40 (1.21-1.63) | <.001 | 1.40 (1.21-1.61) | <.001 |
| Chronic GVHD with steroid | 87 | 1.84 (1.63-2.07) | <.001 | 1.83 (1.63-2.05) | <.001 |
| Patient age at sample, continuous (per decade) | 186 | 1.08 (1.03-1.13) | .003 | 1.07 (1.03-1.12) | .001 |
| Patient sex | |||||
| Male | 96 | Reference | |||
| Female | 90 | 0.99 (0.87-1.13) | .92 | ||
| Race | |||||
| White | 167 | Reference | |||
| Others | 19 | 0.92 (0.74-1.14) | .45 | ||
| Stem cell source | .06† | ||||
| Peripheral blood stem cell | 162 | Reference | |||
| Bone marrow | 18 | 0.82 (0.66-1.03) | .083 | ||
| Cord blood | 5 | 0.65 (0.44-0.97) | .035 | ||
| Missing | 1 | 0.74 (0.31-1.80) | .51 | ||
| Conditioning intensity | |||||
| Myeloablative | 96 | Reference | |||
| Reduced intensity | 90 | 1.17 (1.03-1.33) | .02 | ||
| Donor type | .29† | ||||
| HLA-matched relative | 68 | Reference | |||
| HLA-mismatched relative | 7 | 0.94 (0.66-1.34) | .75 | ||
| Unrelated donor | 111 | 1.10 (0.96-1.27) | .16 | ||
| Female donor to a male recipient | 37 | 1.05 (0.89-1.24) | .57 | ||
| Prior grade 2-4 acute GVHD | 108 | 0.99 (0.86-1.13) | .84 | ||
| Duration from HCT to sample draw per y | 186 | 1.08 (1.02-1.15) | .007 | ||
| NIH global severity | <.001† | ||||
| None or mild | 101 | Reference | |||
| Moderate | 35 | 1.41 (1.20-1.66) | <.001 | ||
| Severe | 50 | 1.51 (1.31-1.75) | <.001 | ||
| Involved sites | |||||
| Skin | 74 | 1.40 (1.24-1.58) | <.001 | ||
| Mouth | 58 | 1.34 (1.17-1.54) | <.001 | ||
| Eye | 72 | 1.51 (1.34-1.71) | <.001 | ||
| Gastrointestinal tract | 24 | 1.32 (1.09-1.60) | .005 | ||
| Liver | 5 | 1.24 (0.83-1.86) | .29 | ||
| Lung (bronchiolitis obliterans) | 4 | 1.38 (0.88-2.16) | .16 | ||
| Joint/fascia | 57 | 1.38 (1.21-1.58) | <.001 | ||
| Genital | 15 | 1.15 (0.91-1.47) | .24 | ||